

MIC-A

Catalog # PVGS1087

Product Information

Primary Accession Q29983
Species Human

Sequence Glu24-Asp255 (Thr47Ala, Cys59Tyr, Lys148Glu, Met152Val, Lys196Glu,

Gly229Ser, Trp233Arg, Thr236Ile, Ser238Thr)

Purity > 95% as analyzed by SDS-PAGE

> 95% as analyzed by HPLC

Endotoxin Level

Biological Activity Fully biologically active when compared to standard. The specific activity is

determined by binding MICA antibody in ELISA.

Expression System E. coli

Theoretical Molecular Weight 32.8 kDa

Formulation Reconstitution

Lyophilized from a 0.2 Im filtered concentrated solution in PBS, pH 7.4. It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a

concentration of 0.1-1.0 mg/ml.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at -20°C or

-70°C. Upon reconstitution, the product should be stable for up to 1 week at

2-8°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information

Gene ID 100507436

Other Names MHC class I polypeptide-related sequence A, MIC-A, MICA

{ECO:0000312|EMBL:CAI41907.1}

Target Background MIC-A (MHC class I chain-related gene A) is a transmembrane glycoprotein

that functions as a ligand for human NKG2D. A closely related protein, MICB, shares 85% amino acid identity with MICA. These proteins are distantly related to the MHC class I proteins. They possess three extracellular Ig-like

domains, but they have no capacity to bind peptide or interact with

ß2-microglobulin. The genes encoding these proteins are found within the Major Histocompatibility Complex on human chromosome 6. The MICA locus is highly polymorphic with more than 50 recognized human alleles. MICA is absent from most cells but is frequently expressed in epithelial tumors and can be induced by bacterial and viral infections. MICA is a ligand for human

NKG2D, an activating receptor expressed on NK cells, NKT cells, $\gamma\delta$ T cells, and CD8+ $\alpha\beta$ T cells. Recognition of MICA by NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. MICA recognition is involved in tumor surveillance, viral infections, and autoimmune diseases.

Protein Information

Name

MICA {ECO:0000312 | EMBL:CAI41907.1}

Function

Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells (PubMed:11491531, PubMed:11777960). Up- regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells resulting in a range of immune effector functions, such as cytotoxicity and cytokine production (PubMed:10426993).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Cytoplasm Note=Expressed on the cell surface in gastric epithelium, endothelial cells and fibroblasts and in the cytoplasm in keratinocytes and monocytes. Infection with human adenovirus 5 suppresses cell surface expression due to the adenoviral E3-19K protein which causes retention in the endoplasmic reticulum.

Tissue Location

Widely expressed with the exception of the central nervous system where it is absent. Expressed predominantly in gastric epithelium and also in monocytes, keratinocytes, endothelial cells, fibroblasts and in the outer layer of Hassal's corpuscles within the medulla of normal thymus. In skin, expressed mainly in the keratin layers, basal cells, ducts and follicles. Also expressed in many, but not all, epithelial tumors of lung, breast, kidney, ovary, prostate and colon. In thyomas, overexpressed in cortical and medullar epithelial cells. Tumors expressing MICA display increased levels of gamma delta T-cells.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.